Your browser is no longer supported. Please, upgrade your browser.
ICPT Intercept Pharmaceuticals, Inc. daily Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.87 Insider Own2.20% Shs Outstand33.24M Perf Week6.22%
Market Cap3.79B Forward P/E- EPS next Y-10.33 Insider Trans-8.65% Shs Float25.66M Perf Month36.03%
Income-334.50M PEG- EPS next Q-2.61 Inst Own82.30% Short Float21.24% Perf Quarter58.01%
Sales233.80M P/S16.23 EPS this Y24.50% Inst Trans-1.24% Short Ratio8.90 Perf Half Y35.76%
Book/sh4.00 P/B28.54 EPS next Y0.40% ROA-51.40% Target Price148.00 Perf Year5.62%
Cash/sh21.43 P/C5.33 EPS next 5Y-8.89% ROE-495.50% 52W Range56.76 - 131.87 Perf YTD13.27%
Dividend- P/FCF- EPS past 5Y-23.60% ROI-73.10% 52W High-13.43% Beta1.47
Dividend %- Quick Ratio5.50 Sales past 5Y156.40% Gross Margin98.80% 52W Low101.13% ATR5.28
Employees330 Current Ratio5.50 Sales Q/Q31.90% Oper. Margin- RSI (14)66.80 Volatility4.98% 5.00%
OptionableYes Debt/Eq4.02 EPS Q/Q-19.10% Profit Margin- Rel Volume1.30 Prev Close115.93
ShortableYes LT Debt/Eq4.02 EarningsNov 05 BMO Payout- Avg Volume612.48K Price114.16
Recom1.80 SMA2011.66% SMA5037.62% SMA20038.41% Volume796,239 Change-1.53%
Dec-02-19Initiated Canaccord Genuity Buy
Sep-04-19Upgrade Citigroup Neutral → Buy $106 → $85
Jun-25-19Initiated Stifel Hold $89
May-10-19Reiterated B. Riley FBR Buy $169 → $158
May-03-19Upgrade Wells Fargo Market Perform → Outperform
Mar-01-19Upgrade RBC Capital Mkts Sector Perform → Outperform $130
Feb-22-19Downgrade SVB Leerink Mkt Perform → Underperform $70
Feb-15-19Reiterated BofA/Merrill Underperform $68 → $79
Feb-04-19Upgrade Raymond James Outperform → Strong Buy $184
Jan-31-19Initiated Credit Suisse Outperform $167
Jan-30-19Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jan-23-19Initiated UBS Buy $130
Jan-14-19Upgrade Laidlaw Hold → Buy $130
Dec-12-18Initiated B. Riley FBR Buy $155
Nov-19-18Upgrade Oppenheimer Perform → Outperform
Oct-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-01-18Resumed Cantor Fitzgerald Overweight $170
Sep-12-18Initiated ROTH Capital Buy $192
Aug-15-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-06-18Upgrade Goldman Sell → Buy
Dec-13-19 08:00AM  Intercept Provides Regulatory Update GlobeNewswire
Dec-10-19 03:36PM  Genfit Hopes to Buck the Odds With NASH Drug GuruFocus.com
08:00AM  Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York GlobeNewswire
Dec-05-19 07:00PM  Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet GlobeNewswire
11:31AM  Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 04:50AM  Is Intercept Pharmaceuticals (NASDAQ:ICPT) Using Debt In A Risky Way? Simply Wall St.
Dec-02-19 09:04AM  Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space Zacks
08:00AM  Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer GlobeNewswire
Nov-29-19 11:24AM  The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx Zacks
10:29AM  These 3 Biotech Stocks Could More Than Double in 2020, Says Wedbush TipRanks
08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-27-19 10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks +7.56%
Nov-26-19 11:07AM  Company News For Nov 26, 2019 Zacks +5.35%
08:24AM  Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
Nov-25-19 04:20PM  This Biotech Popped After Its Rival Crashed 76% On A Scrapped Test Investor's Business Daily +8.38%
08:00AM  FDA Accepts Intercepts NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review GlobeNewswire
Nov-22-19 02:27AM  Edited Transcript of ICPT earnings conference call or presentation 5-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-08-19 07:00AM  New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH GlobeNewswire
Nov-06-19 10:34AM  Intercept (ICPT) Earnings and Sales Miss Estimates in Q3 Zacks +6.24%
Nov-05-19 08:35AM  Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM  Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Oct-29-19 08:00AM  Intercept to Announce Third Quarter 2019 Financial Results on November 5, 2019 GlobeNewswire
Oct-28-19 08:00AM  Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019 GlobeNewswire
Oct-23-19 02:14PM  Hedge Funds Have Never Been This Bullish On Intercept Pharmaceuticals Inc (ICPT) Insider Monkey
10:34AM  Analysts Estimate Intercept Pharmaceuticals (ICPT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-21-19 10:19AM  Does Market Volatility Impact Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price? Simply Wall St.
Oct-18-19 11:22AM  New Gilead CFO: Let's Make a Deal GuruFocus.com
Oct-11-19 05:10PM  Startup with eye on fatty liver disease NASH lays out $70M IPO plan American City Business Journals
Sep-27-19 04:05PM  Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH GlobeNewswire
Sep-26-19 04:16PM  This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years Investor's Business Daily
11:40AM  Enanta's Stock Down Despite NASH Drug Meeting Goal in Study Zacks
Sep-25-19 08:00AM  Intercept to Present at Upcoming Investor Conference in October GlobeNewswire
Sep-13-19 09:47AM  Who Has Been Selling Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares? Simply Wall St.
Sep-11-19 08:00AM  Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH GlobeNewswire
Sep-09-19 10:00AM  Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics Motley Fool
08:00AM  Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations GlobeNewswire
Sep-06-19 09:31AM  Why Is Intercept (ICPT) Down 2.5% Since Last Earnings Report? Zacks
Aug-26-19 12:00AM  3 Small-Cap Stocks With Big-Cap Potential Motley Fool
Aug-23-19 08:00AM  Intercept to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-19-19 02:45PM  Obesity Epidemic Leads To A New Problem And It Could Be Worth Billions Investor's Business Daily
Aug-12-19 07:28PM  Edited Transcript of ICPT earnings conference call or presentation 7-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 09:26AM  Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus Zacks +7.38%
05:59AM  Investors Who Bought Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Five Years Ago Are Now Down 79% Simply Wall St.
Aug-07-19 09:23PM  Intercept Pharmaceuticals Inc (ICPT) Q2 2019 Earnings Call Transcript Motley Fool
03:00PM  What You'll Want to Know About Intercept Pharmaceuticals' Q2 Update Motley Fool
08:25AM  Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:05AM  Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-31-19 08:00AM  Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019 GlobeNewswire
Jul-25-19 10:33AM  Will Intercept Pharmaceuticals (ICPT) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-24-19 06:00AM  3 Top Healthcare Stocks to Buy in July Motley Fool
Jul-16-19 10:28AM  4 Strong Buy Biotechs With Big 3Q19 Catalysts TipRanks
Jun-30-19 02:00PM  Better Buy: Intercept Pharmaceuticals vs. CV Sciences Motley Fool
Jun-21-19 01:42PM  An Intrinsic Calculation For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Suggests It's 43% Undervalued Simply Wall St.
Jun-17-19 01:50PM  ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention Benzinga +5.75%
Jun-13-19 09:06PM  Is Intercept Pharmaceuticals Inc (ICPT) A Good Stock To Buy? Insider Monkey
Jun-12-19 06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
Jun-11-19 08:58AM  CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors MarketWatch
Jun-07-19 09:30AM  Why Is Intercept (ICPT) Down 5.2% Since Last Earnings Report? Zacks
Jun-06-19 04:33PM  Biotech Stocks Tumble As FDA Doubts Method Of Testing Drugs Investor's Business Daily -5.74%
11:44AM  ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study Benzinga
May-30-19 01:25PM  7 Stocks to Buy for Monster Growth InvestorPlace
07:00AM  Intercept to Present at Upcoming Investor Conferences in June GlobeNewswire
May-23-19 10:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-19-19 09:00AM  Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences Motley Fool
May-16-19 06:11AM  Edited Transcript of ICPT earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-10-19 04:05PM  Intercept to Present at Upcoming Investor Conferences in May GlobeNewswire
May-09-19 02:00PM  Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat Zacks
09:00AM  2 Reasons Intercept Pharmaceuticals Stock Tanked in April Motley Fool
07:56AM  The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut Benzinga
May-08-19 04:05PM  Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026 GlobeNewswire
03:00PM  What You Need to Know About Intercept Pharmaceuticals' Great Q1 Performance Motley Fool
12:23PM  Intercept Pharmaceuticals Inc (ICPT) Q1 2019 Earnings Call Transcript Motley Fool
08:55AM  Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:04AM  Will Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Earnings Grow In The Next Couple Of Years? Simply Wall St.
07:48AM  Intercept: 1Q Earnings Snapshot Associated Press
07:00AM  Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-01-19 07:00AM  Intercept to Announce First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-27-19 08:16AM  2 Reasons Gilead Sciences' NASH Program Could Bounce Back Motley Fool
Apr-26-19 12:05PM  Heres What Hedge Funds Think About Intercept Pharmaceuticals Inc (ICPT) Insider Monkey
Apr-25-19 10:13AM  Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment Benzinga
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
Apr-16-19 07:43PM  3 Top Healthcare Stocks to Buy in April Motley Fool
Apr-15-19 04:26PM  Gilead to Collaborate with Novo Nordisk for NASH Treatment Zacks
Apr-11-19 09:16PM  Why Intercept's Success Was a Big Disappointment Motley Fool -13.20%
04:39PM  Why Intercept Pharmaceuticals, Weight Watchers International, and Canopy Growth Slumped Today Motley Fool
11:26AM  Is Intercept Pharma's Updated Late-Stage NASH Data A Sell-The-News Event? Benzinga
10:03AM  Intercept Reports Additional Positive Data From NASH Study Zacks
07:48AM  The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug Benzinga
02:00AM  Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH GlobeNewswire
Apr-07-19 05:04PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
Apr-04-19 07:00AM  Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress 2019 GlobeNewswire
Apr-02-19 07:44PM  Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences Motley Fool
Apr-01-19 04:57PM  Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics Zacks
Mar-31-19 09:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Mar-30-19 11:31AM  2 Biotechs With Big Dates in April Motley Fool
10:15AM  How Many Insiders Sold Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares? Simply Wall St.
09:30AM  Why Is Intercept (ICPT) Up 12.2% Since Last Earnings Report? Zacks
Mar-22-19 05:43PM  Conatus (CNAT) Declines on Failure of NASH Fibrosis Study Zacks
10:49AM  Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo Benzinga
Mar-06-19 10:44PM  Edited Transcript of ICPT earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cawkwell GailSVP, Med Affairs, Safety & PVDec 03Option Exercise54.63804,37018,722Dec 05 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 27Option Exercise59.1092754,78416,686Dec 02 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 27Sale101.651,040105,71615,646Dec 02 07:00 PM
Pruzanski MarkPresident & CEONov 26Option Exercise14.3035,437506,769504,563Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 26Option Exercise59.114,373258,49120,132Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 26Sale100.004,373437,30015,759Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 26Sale100.0035,4373,543,700469,126Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 25Option Exercise8.6714,563126,213483,689Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 25Option Exercise59.101,855109,62817,614Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 25Sale100.001,855185,50015,759Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 25Sale100.0014,5631,456,300469,126Nov 27 07:00 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 19Option Exercise53.418,325444,63834,043Nov 19 07:00 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 19Sale85.0012,1541,033,09021,889Nov 19 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 19Sale85.001,550131,75015,759Nov 19 07:01 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 13Option Exercise53.4150026,70526,929Nov 15 07:02 PM
Weyer ChristianEVP, Research & DevelopmentNov 13Sale85.0094680,41017,309Nov 15 07:01 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 13Sale85.0050042,50026,429Nov 15 07:02 PM
Bright LisaPresident, InternationalOct 29Sale75.0059544,62518,732Oct 31 07:00 PM
Ford David AChief Human Resources OfficerOct 23Sale70.00584,06011,396Oct 25 07:00 PM
Ford David AChief Human Resources OfficerSep 16Sale70.0080056,00011,546Sep 18 07:00 PM
AKKARAJU SRINIVASDirectorAug 28Buy60.325,207314,086403,688Aug 30 02:32 PM
Bright LisaPresident, InternationalJul 03Sale78.6659546,80319,857Jul 03 05:00 PM
Fundaro PaoloDirectorMay 20Option Exercise15.246,749102,88717,863May 22 07:00 PM
Benatti LucaDirectorMay 14Buy83.501,200100,2007,556May 14 07:00 PM
Shapiro DavidChief Medical OfficerMay 01Option Exercise31.902,00063,80041,499May 03 07:00 PM
Shapiro DavidChief Medical OfficerMay 01Sale86.282,000172,56039,499May 03 07:00 PM
AKKARAJU SRINIVASDirectorApr 25Option Exercise24.473,50085,66019,956Apr 29 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVApr 18Option Exercise54.631,75095,60319,599Apr 22 07:01 PM
Shapiro DavidChief Medical OfficerApr 15Option Exercise31.902,00063,80041,499Apr 16 07:01 PM
Shapiro DavidChief Medical OfficerApr 15Sale95.002,000190,00039,499Apr 16 07:01 PM
Bright LisaPresident, InternationalApr 03Sale115.0159468,31620,982Apr 03 07:01 PM
Shapiro DavidChief Medical OfficerApr 03Sale115.0156264,63639,499Apr 03 07:00 PM
Fundaro PaoloDirectorMar 29Sale107.452,171233,27211,114Mar 29 07:00 PM
Shapiro DavidChief Medical OfficerMar 01Option Exercise31.902,00063,80042,543Mar 01 07:00 PM
Shapiro DavidChief Medical OfficerMar 01Sale103.162,000206,32040,543Mar 01 07:00 PM
Weyer ChristianEVP, Research & DevelopmentMar 01Sale103.1633334,35219,107Mar 01 07:00 PM
AKKARAJU SRINIVASDirectorFeb 19Sale128.7823,4383,018,346210,937Feb 21 08:33 PM
Shapiro DavidChief Medical OfficerFeb 15Option Exercise31.902,00063,80042,543Feb 20 09:01 PM
Shapiro DavidChief Medical OfficerFeb 15Sale111.512,000223,02040,543Feb 20 09:01 PM
Bright LisaPresident, InternationalJan 07Sale104.931,313137,77318,807Jan 09 08:00 PM
Shapiro DavidChief Medical OfficerJan 04Sale97.4847446,20637,243Jan 04 07:01 PM
Shapiro DavidChief Medical OfficerJan 03Sale97.4569968,11837,717Jan 03 07:04 PM
Shapiro DavidChief Medical OfficerJan 02Option Exercise31.902,00063,80040,416Jan 03 07:04 PM
Shapiro DavidChief Medical OfficerJan 02Sale98.282,000196,56038,416Jan 03 07:04 PM
Shapiro DavidChief Medical OfficerDec 17Option Exercise31.902,00063,80041,152Dec 19 07:00 PM
Shapiro DavidChief Medical OfficerDec 17Sale106.622,000213,24039,152Dec 19 07:00 PM